You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 49 No. 12, December 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Elevated Neopterin Levels in Guillain-Barré Syndrome

Further Evidence of Immune Activation

Shalini Bansil, MD; Francis A. Mithen, MD, PhD; Bhim S. Singhal, MD, FRCP; Stuart D. Cook, MD; Christine Rohowsky-Kochan, PhD

Arch Neurol. 1992;49(12):1277-1280.


Abstract

• Neopterin is a by-product of guanosine triphosphate metabolism and is produced by macrophages in response to lymphocytic activation. We have studied serum neopterin levels in patients with Guillain-Barré syndrome to obtain further evidence of immune activation in this disease. Serum neopterin levels were significantly elevated in patients with Guillain-Barré syndrome compared with patients with other peripheral neuropathies and multiple sclerosis and with healthy control subjects. Serial analysis demonstrated that as neopterin levels fell, the clinical status of the patients with Guillain-Barré syndrome improved and soluble interleukin 2 receptor levels dropped. Thus, lymphocytic and macrophage activation may play a role in the pathogenesis of Guillain-Barré syndrome.



Author Affiliations

From the Department of Neurosciences, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark (Drs Bansil, Cook, and Rohowsky-Kochan); the Department of Veterans Affairs, John Cochran Medical Center, St Louis, Mo (Dr Mithen); St Louis University, School of Medicine (Dr Mithen); the Department of Neurology, Bombay (India) Hospital (Dr Singhal); and the Neurology Service, Veterans Affairs Medical Center, East Orange, NJ (Dr Cook).


Footnotes

Accepted for publication July 20, 1992.

Reprint requests to University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Department of Neurosciences, MSB H506, 185 S Orange Ave, Newark, NJ 07103 (Dr Bansil).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Therapeutic Apheresis in Neurology Critical Care
Natarajan and Weinstein
J Intensive Care Med 2005;20:212-225.
ABSTRACT  

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients
Cook et al.
Neurology 2001;57:1080-1084.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.